IPO Databook: Ming Yu Pharmaceutical (HK) - Jul 2026

132 Views09 Jul 2026 21:02

SUMMARY

Ming Yu Pharmaceutical, established in 2018, focuses on oncology (ADCs, immunotherapies) and advanced autoimmune assets, seeking HKEX Chapter 18A listing due to profitability.
The company boasts 11 product candidates, including core products MHB036C and MHB018A, leveraging its proprietary SuperTopoi ADC platform with high potency.
Ming Yu reported significant losses, including RMB919,308 in 2025, and net liabilities of RMB2,148,726 as of May 31, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream